Inhaled insulin for diabetes mellitus

New England Journal of Medicine

Volumn 356, Issue 5, 2007, Pages 497-502

  McMahon, Graham T ^a   Arky, Ronald A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ASPART; BRONCHODILATING AGENT; GLITAZONE DERIVATIVE; GLULISINE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA; UNCLASSIFIED DRUG;

ANAMNESIS; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; COUGHING; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; ENDOCRINOLOGY; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INHALER; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING;

EID: 33846651828     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMct063533     Document Type: Article

References (48)

1. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263-8.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
3. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917-32.
4. Insulin and diabetes medication use: data and trends from the National Diabetes Surveillance System. Atlanta: Centers for Disease Control and Prevention, 2005. (Accessed January 8, 2007, at http://www.cdc.gov/Diabetes/ statistics/meduse/dtltable2.htm.)
5. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 2004;26:1498-505.
6. Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol 2003;4:661-7.
7. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the crossnational Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-9.
8. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care 1997;20:292-8.
9. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999;46:239-46.
10. Zambanini A, Feher MD. Needle phobia in type 1 diabetes mellitus. Diabet Med 1997;14:321-3.
11. Zambanini A, McIntosh CS, Mitchell C, Catalan J, Feher MD. Psychological issues in diabetes. Lancet 1999;354:74.
12. Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005;28:427-8.
13. Cefalu WT. Novel routes of insulin delivery for patients with type 1 or type 2 diabetes. Ann Med 2001;33:579-86.
14. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003;289:2254-64.
15. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001;2:198-209.
16. Wearley LL. Recent progress in protein and peptide delivery by noninvasive routes. Crit Rev Ther Drug Carrier Syst 1991;8:331-94.
17. Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst 1995;12:151-231.
18. European public assessment report: Exubera. London: European Medicines Agency, 2006. (Accessed January 8, 2007, at http://www.emea.eu.int/humandocs/ PDFs/EPAR/exubera/058806en6.pdf.)
19. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev 1999;35:235-47.
20. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004;43:781-801.
21. Cefalu WT, Skyler JS, Kourides IA, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001;134:203-7.
22. Rave K, Bott S, Heinemann L, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005;28:1077-82.
23. Ceglia L, Lau J, Pittas AG. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 2006;145:665-75.
24. Statistical review and evaluation of Exubera. Washington, DC: Food and Drug Administration, December 27, 2004. (Accessed January 8, 2007, at http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4169B1_02_05-FDA-Clin- Stats-Efficacy.pdf.)
25. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2622-7.
26. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2356-62.
27. DeFronzo RA, Bergenstal RM, Cefalu WT, et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005;28:1922-8.
28. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005;143:549-58.
29. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 2006;29:1282-7.
30. Idem. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care 2006;29:1818-25.
31. Cappelleri JC, Cefalu WT, Rosenstock J, Kourides IA, Gerber RA. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther 2002;24:552-64.
32. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004;27:1318-23.
33. FDA approves first ever inhaled insulin combination product for treatment of diabetes. Washington, DC: Food and Drug Administration, January 27, 2006. (Accessed January 8, 2007, at http://www.fda.gov/bbs/topics/news/2006/NEW01304. html.)
34. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6.
35. Becker RH, Sha S, Frick AD, Fountaine RJ. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care 2006;29:277-82.
36. Himmelmann A, Jendle J, Mellen A, Petersen AH, Dahl UL, Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care 2003;26:677-82.
37. Advisory Committee briefing document: Exubera. New York: Pfizer Pharmaceuticals, August 3, 2005. (Accessed January 8, 2007, at http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4169B1_01_01-Pfizer- Exubera.pdf.)
38. Exubera. New York: Pfizer, January 2006 (package insert). (Accessed January 8, 2007, at http://www.fda.gov/cder/foi/label/2006/021868lbl.pdf.)
39. Product overview: Exubera. London: European Medicines Agency, January 24, 2006. (Accessed January 8, 2007, at http://www.emea.eu.int/humandocs/Humans/ EPAR/exubera/exubera.htm.)
40. Sanderson I, Cacciatore K, Goater J, Scala S, Fernandez S. Exubera pricing more competitive than forecast. New York: S.G. Cowen, June 22, 2006.
41. 2006 Red Book: pharmacy's fundamental reference. Montvale, NJ: Thomson/PDR, 2006.
42. Skyler JS, Weinstock RS, Raskin P, et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005;28:1630-5.
43. Ramirez LC, Dal Nogare A, Hsia C, et al. Relationship between diabetes control and pulmonary function in insulin-dependent diabetes mellitus. Am J Med 1991;91:371-6.
44. Hsia CC, Raskin P. The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med 2005;118:205-11.
45. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes: an analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005;90:3287-94.
46. Sadri H, MacKeigan LD, Leiter LA, Einarson TR. Willingness to pay for inhaled insulin: a contingent valuation approach. Pharmacoeconomics 2005;23:1215-27.
47. Inhaled insulin for the treatment of diabetes (types 1 and 2). London: National Institute for Health and Clinical Excellence, December 2006. (Accessed January 8, 2007, at http://www.nice.org.uk/TA113.)
48. Inhaled insulin (Exubera): Rapid Report 01. Cologne, Germany: Institute for Quality and Efficiency in Health Care, April 2006.